Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Breast cancer metastasis to the central nervous system Weil RJ; Palmieri DC; Bronder JL; Stark AM; Steeg PSAm J Pathol 2005[Oct]; 167 (4): 913-20Clinically symptomatic metastases to the central nervous system (CNS) occur in approximately 10 to 15% of patients with metastatic beast cancer. CNS metastases are traditionally viewed as a late complication of systemic disease, for which few effective treatment options exist. Recently, patients with Her-2-positive breast tumors who were treated with trastuzumab have been reported to develop CNS metastases at higher rates, often while responding favorably to treatment. The blood:brain barrier and the unique brain microenvironment are hypothesized to promote distinct molecular features in CNS metastases that may require tailored therapeutic approaches. New research approaches using cell lines that reliably and preferentially metastasize in vivo to the brain have been reported. Using such model systems, as well as in vitro analogs of blood-brain barrier penetration and tissue-based studies, new molecular leads into this disease are unfolding.|Antibodies, Monoclonal, Humanized[MESH]|Antibodies, Monoclonal/adverse effects[MESH]|Antineoplastic Agents/adverse effects[MESH]|Blood-Brain Barrier[MESH]|Breast Neoplasms/diagnostic imaging/drug therapy/*pathology[MESH]|Cell Line, Tumor[MESH]|Central Nervous System Neoplasms/diagnostic imaging/drug therapy/*pathology/*secondary[MESH]|Female[MESH]|Humans[MESH]|Models, Biological[MESH]|Receptor, ErbB-2[MESH]|Survival Analysis[MESH]|Tomography, X-Ray Computed[MESH]|Trastuzumab[MESH] |